Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

November 29, 2021 7:11 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Krystal Biotech (NASDAQ: KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Momentum Movers, Trader Talk